Physician profile
Roseline Otunga
NPI 1770176661
$683.51
in general payments reported to CMS, 2019-2025
11 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $150 · 2024: $350 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $662 · Education: $21.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $662.31 |
| Education | $21.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $220.62 | 2024-2025 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $116.30 | 2023-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $78.24 | 2023-2024 | |
| Amgen INC. | $76.85 | 2023-2024 | Parsabiv, Tavneos, Aranesp |
| Astrazeneca Pharmaceuticals LP | $58.21 | 2024 | |
| Akebia Therapeutics INC | $28.18 | 2025 | Vafseo |
| Vifor Pharma, INC. | $24.22 | 2023 | Veltassa |
| Ani Pharmaceuticals, INC. | $21.91 | 2024 | Purified Cortrophin Gel |
| Opko Pharmaceuticals, LLC | $21.20 | 2023 | Rayaldee |
| Fresenius USA Marketing, INC. | $20.46 | 2024 | Velphoro |
| Lilly USA, LLC | $17.32 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roseline Otunga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.